share_log

Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed With Enhanced Host Conditioning

Moomoo 24/7 ·  Apr 4 06:32
  • Improved VELOS manufacturing process delivering higher cNeT doses.
  • Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
  • First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment